Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

Moksi Apr. 10 at 2:50 AM

$RFL can’t wait for June 20-50$

0 · Reply

GDS_investing Apr. 9 at 6:35 PM

$RFL nice long

0 · Reply

Moksi Apr. 9 at 5:51 PM

$RFL let’s go

0 · Reply

Love_To_Learn Apr. 8 at 11:36 AM

$OMEX 1.52 SUPER FILLER FOR $RFL ACTIVE *

1 · Reply

CaseOfTheYips1 Apr. 6 at 6:26 PM

$RFL By mid-June our future will be decided. I anticipate approval with a generous safety label, although I don’t see any acquisition interest… commercialization will be the kicker… do they go alone or partner… it’s expensive and dilution inevitable… how to play the timing is the million dollar question… Where is MWT to see this through?!?! With less than two months to go he should come out of the ashes and phoenix on all those haters…

0 · Reply

northmark1 Apr. 6 at 5:59 PM

$RFL Somebody Posted this was going to $6.00 By September.... BAHAHAHAAA!!! Pumpers will do anything to save there Bad investment in this Piece of Shit Stock...

1 · Reply

GDS_investing Apr. 6 at 12:56 PM

$ZIM $RFL $VTVT all long

1 · Reply

Moksi Apr. 4 at 6:03 PM

$RFL

0 · Reply

Moksi Apr. 3 at 3:46 AM

$RFL

0 · Reply

northmark1 Mar. 31 at 6:45 PM

$RFL Pumpers Be Pumping!! Everyone else using this stock to wipe their Ass....

0 · Reply

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Dec 11, 2025, 4:01 PM EST - 4 months ago

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Oct 29, 2025, 4:24 PM EDT - 5 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 5 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Sep 16, 2025, 8:00 AM EDT - 7 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Aug 27, 2025, 8:00 AM EDT - 8 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Jun 11, 2025, 7:00 AM EDT - 10 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 11 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 11 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 1 year ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 1 year ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 1 year ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 4 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Moksi Apr. 10 at 2:50 AM

$RFL can’t wait for June 20-50$

0 · Reply

GDS_investing Apr. 9 at 6:35 PM

$RFL nice long

0 · Reply

Moksi Apr. 9 at 5:51 PM

$RFL let’s go

0 · Reply

Love_To_Learn Apr. 8 at 11:36 AM

$OMEX 1.52 SUPER FILLER FOR $RFL ACTIVE *

1 · Reply

CaseOfTheYips1 Apr. 6 at 6:26 PM

0 · Reply

northmark1 Apr. 6 at 5:59 PM

$RFL Somebody Posted this was going to $6.00 By September.... BAHAHAHAAA!!! Pumpers will do anything to save there Bad investment in this Piece of Shit Stock...

1 · Reply

GDS_investing Apr. 6 at 12:56 PM

$ZIM $RFL $VTVT all long

1 · Reply

Moksi Apr. 4 at 6:03 PM

$RFL

0 · Reply

Moksi Apr. 3 at 3:46 AM

$RFL

0 · Reply

northmark1 Mar. 31 at 6:45 PM

$RFL Pumpers Be Pumping!! Everyone else using this stock to wipe their Ass....

0 · Reply

MrBruceWayne Mar. 30 at 11:24 AM

🚨💎 BUY ALERT $RFL

1 · Reply

OfficialStocktwitsUser Mar. 24 at 12:33 AM

$RFL RSI: 29.79, MACD: 0.0009 Vol: 0.10, MA20: 1.36, MA50: 1.27 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GDS_investing Mar. 23 at 5:45 PM

$VTVT It's quiet here today. $ZIM $RFL $AGEN $BHC

0 · Reply

PenkeInvesting Mar. 20 at 12:13 AM

Fundamental analysis of $RFL (Rafael Holdings, Inc.) based on financial data and reported results. #RFL #Rafael

0 · Reply

ReposedAnchor Mar. 17 at 5:53 PM

$RFL

0 · Reply

GDS_investing Mar. 17 at 4:46 PM

$RFL “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.

1 · Reply

GDS_investing Mar. 17 at 4:46 PM

$RFL “We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,” said Joshua Fine, Chief Operating Officer of Rafael Holdings.

0 · Reply

GDS_investing Mar. 17 at 4:26 PM

$RFL

0 · Reply

jujusmithstockster Mar. 17 at 3:22 PM

$RFL this would have to reach $30 doll haira before i ever recoup my losses from merger... anyone in here think that's EVER possible lol

1 · Reply

Moksi Mar. 17 at 6:22 AM

$RFL

0 · Reply

Pizzino Mar. 16 at 9:39 PM

$RFL

0 · Reply

CaseOfTheYips1 Mar. 16 at 9:19 PM

$RFL what is the world did they spend $12M in R&D? Zero news on that one Joshua… ya fired

0 · Reply

Market Cap	62.94M
Revenue (ttm)	920,000.00
Net Income (ttm)	-30.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,317.39%
Debt to Equity Ratio	0.01

Volume	57,100
Avg Vol	79,086
Day's Range	N/A - N/A
Shares Out	52.01M
Stochastic %K	67%
Beta	0.51
Analysts	Strong Buy
Price Target	N/A